Business Description
Immunic Inc
NAICS : 541714
SIC : 2834
ISIN : US92847R1041
Description
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 34.99 | |||||
| Equity-to-Asset | 0.53 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 10.5 | |||||
| 3-Year EPS without NRI Growth Rate | 9.1 | |||||
| 3-Year FCF Growth Rate | 18.4 | |||||
| 3-Year Book Growth Rate | -56 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.62 | |||||
| 9-Day RSI | 50.91 | |||||
| 14-Day RSI | 49.41 | |||||
| 6-1 Month Momentum % | 26.09 | |||||
| 12-1 Month Momentum % | -17.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.12 | |||||
| Quick Ratio | 2.12 | |||||
| Cash Ratio | 1.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.7 | |||||
| Shareholder Yield % | -0.5 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -133.15 | |||||
| ROA % | -104.8 | |||||
| ROIC % | -2634.57 | |||||
| ROC (Joel Greenblatt) % | -5113.01 | |||||
| ROCE % | -139.16 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.98 | |||||
| Price-to-Tangible-Book | 1.99 | |||||
| EV-to-EBIT | -0.7 | |||||
| EV-to-EBITDA | -0.7 | |||||
| EV-to-FCF | -0.97 | |||||
| Price-to-Net-Current-Asset-Value | 2.13 | |||||
| Price-to-Net-Cash | 2.73 | |||||
| Earnings Yield (Greenblatt) % | -142.86 | |||||
| FCF Yield % | -62.2 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers